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Background: Galectin-3 is involved in processes which are pivotal contributing pathophysiological mechanisms in the development and 
progression of heart failure (HF). Galectin-3 has been tested as a biomarker in acute HF. Here we describe the usefulness of galectin-3 in a large 
cohort of chronic HF patients.
Methods: We studied 592 patients with HF who were enrolled in a large multicenter study (COACH) in the Netherlands, and who were followed 
for 18 months. Plasma galectin-3 levels were measured using an ELISA (developed by BG Medicine, Waltham, MA, USA). The primary endpoint of 
the study was a composite of all-cause mortality and HF hospitalization. The prognostic value of galectin-3 was investigated using univariate and 
multivariate analysis.
Results: The mean age of the patients was 72±12 years, and 65% was male. 50% was in NYHA class II and 50% was in NYHA class III-IV. Mean 
LVEF was 33±15%, mean eGFR was 55 mL/min/1.73m2 and mean BNP was 448 pg/mL. During follow-up, 248 patients reached the primary 
endpoint (164 died). Higher galectin-3 levels were associated with advanced age, worse renal function and higher BNP levels (all P<0.001). 
Furthermore, higher galectin-3 levels were associated with increasing levels of the cytokines IL-10 (P<0.0001) and IL-6 (P=0.001), but not with other 
pro-inflammotory markers like CRP (P=0.083), TNF-alpha (P=0.61) and IL-1beta (P=0.98), nor with the profibrotic marker TGF-beta (P=0.97).
A doubling of galectin-3 levels was associated with a hazard ratio (HR) of 1.99 (95% CI: 1.63-2.43) for developing the primary outcome (P<0.0001). 
After correction for age, gender, BNP and eGFR, the HR was 1.44 (1.12-1.86; P=0.0052). After multi-adjustment for all serum inflammatory and 
fibrotic markers as well as age, gender and BNP, galectin-3 levels were still independently associated with worse outcome (HR 1.54 (1.21-1.97); 
P=0.001).
Conclusions: Galectin-3 is a powerful and independent marker for outcome in chronic HF. Galectin-3 has incremental predictive value for 
outcome, and seems to have limited association with other established biomarkers of heart failure, like BNP, renal function, and inflammatory 
markers.
